| Jennell C Duey, MD | |
|
2675 Central Ave, Billings, MT 59102-6686 | |
| (406) 238-2500 | |
| Not Available |
| Full Name | Jennell C Duey |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 21 Years |
| Location | 2675 Central Ave, Billings, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275619918 | NPI | - | NPPES |
| 0159698 | Other | MT | MDCD PIN |
| 123541900 | Other | MT | MDCD PIN |
| 000095106 | Other | MT | BCBS PIN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 10936 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Compassus Home Health - Billings | Billings, MT | Home health agency |
| Billings Clinic | Billings, MT | Hospital |
| Beartooth Billings Clinic | Red lodge, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Billings Clinic | 6002993516 | 659 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.
Boston-based Veritas Genetics, a pioneer in accessible genetic screening for disease prevention and early detection, received its first European CE mark approval for the company's hereditary breast and ovarian cancer genetic screening test, myBRCA. Veritas introduced myBRCA, which sequences BRCA1 and BRCA2 genes using proprietary gene-targeting technology and Next Generation Sequencing, in North America in May 2015.
For more than 5 million Americans with heart failure, a critical step to better health is taking the medications they're prescribed. But many patients fail to do so, putting themselves at greater risk of hospitalization and even death. To date, studies have not fully answered why patients fall short when it comes to taking heart medicine. In a study appearing in the April issue of Mayo Clinic Proceedings, Mayo Clinic researchers found the drugs' cost is one of the biggest deterrents.
The Associated Press: An effort to streamline the entangled field of Medicare drug plans could mean as many as 3 million seniors "could force 3 million seniors to switch plans next year whether they like it or not, says an independent analysis," by Avalere Health: "beneficiaries will see their prescription plan eliminated as part of a new effort by Medicare to winnow down duplicative coverage and offer consumers more meaningful choices. Seniors would not lose coverage, but they could see changes in their premiums and copayments."
› Verified 6 days ago
| Entity Name | Billings Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326104845 PECOS PAC ID: 6002993516 Enrollment ID: O20080430000212 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.
Boston-based Veritas Genetics, a pioneer in accessible genetic screening for disease prevention and early detection, received its first European CE mark approval for the company's hereditary breast and ovarian cancer genetic screening test, myBRCA. Veritas introduced myBRCA, which sequences BRCA1 and BRCA2 genes using proprietary gene-targeting technology and Next Generation Sequencing, in North America in May 2015.
For more than 5 million Americans with heart failure, a critical step to better health is taking the medications they're prescribed. But many patients fail to do so, putting themselves at greater risk of hospitalization and even death. To date, studies have not fully answered why patients fall short when it comes to taking heart medicine. In a study appearing in the April issue of Mayo Clinic Proceedings, Mayo Clinic researchers found the drugs' cost is one of the biggest deterrents.
The Associated Press: An effort to streamline the entangled field of Medicare drug plans could mean as many as 3 million seniors "could force 3 million seniors to switch plans next year whether they like it or not, says an independent analysis," by Avalere Health: "beneficiaries will see their prescription plan eliminated as part of a new effort by Medicare to winnow down duplicative coverage and offer consumers more meaningful choices. Seniors would not lose coverage, but they could see changes in their premiums and copayments."
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennell C Duey, MD Po Box 35100, Billings, MT 59107-5100 Ph: (406) 238-2500 | Jennell C Duey, MD 2675 Central Ave, Billings, MT 59102-6686 Ph: (406) 238-2500 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.
Boston-based Veritas Genetics, a pioneer in accessible genetic screening for disease prevention and early detection, received its first European CE mark approval for the company's hereditary breast and ovarian cancer genetic screening test, myBRCA. Veritas introduced myBRCA, which sequences BRCA1 and BRCA2 genes using proprietary gene-targeting technology and Next Generation Sequencing, in North America in May 2015.
For more than 5 million Americans with heart failure, a critical step to better health is taking the medications they're prescribed. But many patients fail to do so, putting themselves at greater risk of hospitalization and even death. To date, studies have not fully answered why patients fall short when it comes to taking heart medicine. In a study appearing in the April issue of Mayo Clinic Proceedings, Mayo Clinic researchers found the drugs' cost is one of the biggest deterrents.
The Associated Press: An effort to streamline the entangled field of Medicare drug plans could mean as many as 3 million seniors "could force 3 million seniors to switch plans next year whether they like it or not, says an independent analysis," by Avalere Health: "beneficiaries will see their prescription plan eliminated as part of a new effort by Medicare to winnow down duplicative coverage and offer consumers more meaningful choices. Seniors would not lose coverage, but they could see changes in their premiums and copayments."
› Verified 6 days ago
Michael D. Monday, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1775 Spring Creek Dr, Billings, MT 59102 Phone: 406-373-3500 Fax: 406-373-3520 | |
Aaron James Audet, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Angel M. Eads, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 123 S 27th St, Billings, MT 59101 Phone: 406-247-3220 Fax: 406-651-6406 | |
John Konow, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 123 S 27th St, Billings, MT 59101 Phone: 406-247-3350 Fax: 406-247-3389 | |
Cynthia Kay Brewer, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Dr. Amy Solomon, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 123 S 27th St, Billings, MT 59101 Phone: 406-247-3350 Fax: 406-247-3389 | |
Lawrence A. Hemmer, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2675 Central Ave, Billings, MT 59102 Phone: 406-238-2500 |